Pharmacokinetics and pharmacodynamics of P2Y12 antagonists and on-treatment platelet reactivity with P2Y12 antagonists are potentially influenced by sex, body weight, chronic kidney disease, genetics, smoking, diabetes, body mass, inflammation, and drug–drug interactions [28, 29]. Here, P2RY12 is linked to diabetes mellitus.